Industry insights

Q&A: Lianbang Founder on 29 Years in Medical Oxygen

OxySoothe Editorial

Reported by ifeng.com

Lianbang Medical founder and chairman Xie Bangqing said 29 years of oxygen engineering now underpin a push from hospital systems into home and high-altitude markets. He cited more than 100 patents, a top-three position in the hospital oxygen segment, and an oxygen-diffusion hotel model installed in more than 30 properties.

Keywords: Lianbang Medical, Xie Bangqing, medical oxygen, plateau hotel oxygen

Chengdu Lianbang Medical Technology’s founder and chairman, Xie Bangqing, says the company’s 29 years of oxygen engineering now underpin a push from hospital systems into home and high-altitude markets. He made the comments in an interview with ifeng.com published on 20 April 2026, on the sidelines of an M&A and investment conference in Shenzhen.

His one-line explanation of why the category exists is the clearest part of the interview: “A person can go three days without food, but absolutely not three minutes without oxygen.”

Three oxygen scenarios

Lianbang organises its business around three situations where oxygen supply is inadequate: hospital treatment, high-altitude environments and home health. The hospital segment is the original business — central oxygen supply, medical gas pipelines and PSA generation — and remains the largest by revenue.

The high-altitude segment grew out of the hospital work. Plateau clinics and hotels need oxygen systems that work at low ambient pressure and can be operated by non-clinical staff. The home segment is the newest, and the one the company expects to grow fastest.

That sequence — hospital, then high altitude, then home — is a common path for medical equipment makers, and it is harder than it looks. Each step lowers the technical threshold of the user while raising the threshold of the product: a hospital has engineers, a hotel has a duty manager, a household has nobody. Service design, not just equipment design, decides whether the third step works.

Patents and market position

Xie said the company holds more than 100 patents, including a dozen or so invention patents, and that this base is what keeps it in the top three of the hospital oxygen segment and near the front of the high-altitude segment.

A patent count is a weak signal on its own; the useful question is what the patents cover. For oxygen equipment, the defensible areas are usually the adsorption cycle and valve sequencing in a PSA unit, the oil-free compressor design, and the control logic that keeps purity stable as demand changes. Lianbang’s publicly described core technology is a low-pressure oil-free molecular sieve system that uses a reversing process to cut energy consumption — the compressor is the largest single load in any PSA plant, so efficiency there is the difference between a competitive and an uncompetitive running cost.

The plateau hotel model

The most specific part of the interview concerns altitude tourism. Xie cites more than 60 million visitors a year to China’s plateau regions and says about 80% of them suffer sleep disruption from altitude. The company’s answer is not a portable canister but a building-level service: oxygen is generated on site and diffused into guest rooms, so a guest sleeps in slightly enriched air rather than wearing a mask.

The model, branded “Oxygen Lianbang” (氧联帮), has been installed in more than 30 hotels, according to Xie, with a target of 2,000. The economics depend on occupancy and on whether the hotel can charge a premium for an oxygen room — which is why the company sells the system as a revenue feature rather than a safety cost.

For a hotel operator the engineering questions are unglamorous: where the concentrator sits, how the oxygen is distributed without altering the fire strategy, how purity is monitored, and who responds at 2am if a compressor trips. A supplier that has installed 30 sites should be able to answer all four with a drawing and a service contract.

Capital plans

Lianbang has been listed on China’s National Equities Exchange and Quotations (NEEQ, the “new third board”) since 2016. Xie said the next goal is a main-board listing within three to five years, and that the Shenzhen conference was partly about understanding how AI and capital markets could accelerate that.

For an overseas distributor, a listing plan is worth noting but not worth relying on. It usually means tighter financial reporting and a stronger incentive to grow export revenue; it can also mean a period of cost discipline that shows up in lead times. The practical check is whether the company’s export documentation and after-sales structure are being built now, because those are the parts a listing does not fix.

Source: ifeng.com Shenzhen, 20 April 2026 — https://sz.ifeng.com/c/8sTDo2FSOyt

Tell us your needs

We can tailor a solution for you

Q&A: Lianbang Founder on 29 Years in Medical Oxygen